Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Irinotecan and Cisplatin-Refractory Metastatic Esophageal and Gastric Cancer
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 14 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Nov 2006 Status change